Taiwan Bio Therapeutics Co., Ltd
Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei City, Taiwan.
Taiwan Bio Therapeutics Co., Ltd (6892) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.054x
Based on the latest financial reports, Taiwan Bio Therapeutics Co., Ltd (6892) has a cash flow conversion efficiency ratio of -0.054x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-48.39 Million) by net assets (NT$898.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Taiwan Bio Therapeutics Co., Ltd - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Taiwan Bio Therapeutics Co., Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Taiwan Bio Therapeutics Co., Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Taiwan Bio Therapeutics Co., Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alternative Investment Trust
AU:AIQ
|
0.026x |
|
United Royale Holdings Corp
OTCQB:URYL
|
1.909x |
|
Fingerprint Cards AB (publ)
OTCGREY:FGRRF
|
-0.110x |
|
Yield10 Bioscience Inc
NASDAQ:YTEN
|
0.092x |
|
CSAN3F
SA:CSAN3F
|
N/A |
|
Huatai Tianjin Huatai Securities Assets Management- Jiangsu Traffic Control Reit
SHG:508066
|
N/A |
|
AUST AGRICULTURAL
MU:AY5
|
N/A |
|
Middle East Glass Manufacturing
EGX:MEGM
|
N/A |
Annual Cash Flow Conversion Efficiency for Taiwan Bio Therapeutics Co., Ltd (2020–2024)
The table below shows the annual cash flow conversion efficiency of Taiwan Bio Therapeutics Co., Ltd from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.09 Billion | NT$-252.40 Million | -0.231x | +14.84% |
| 2023-12-31 | NT$613.29 Million | NT$-166.55 Million | -0.272x | -2.20% |
| 2022-12-31 | NT$526.83 Million | NT$-139.99 Million | -0.266x | -15.21% |
| 2021-12-31 | NT$256.50 Million | NT$-59.16 Million | -0.231x | +48.97% |
| 2020-12-31 | NT$67.18 Million | NT$-30.36 Million | -0.452x | -- |